Welcome to our dedicated page for NEUROCRINE BIOSCIENCES SEC filings (Ticker: NBIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neurocrine Biosciences Inc. filings document the regulatory record of a commercial biopharmaceutical company developing and selling treatments for neurological, psychiatric, endocrine and immunological disorders. Its 8-K reports cover operating and financial results, product-sales disclosures, clinical or regulatory updates, material agreements, capital-structure matters and executive or employment-related governance events.
Proxy filings describe board matters, shareholder voting items, executive compensation, equity awards and pay-versus-performance disclosures. The filing record also includes formal disclosures related to INGREZZA, CRENESSITY and the company's pipeline, as well as risk, governance and transaction-related disclosure categories relevant to its public-company status.
Neurocrine Biosciences’ Chief Medical Officer Sanjay Keswani reported routine equity-compensation activity. On June 2 2026, 3,212 restricted stock units (RSUs) vested, each converting into one share of common stock. To cover tax withholding on this vesting, 1,733 shares were withheld by the company at $154.84 per share; no shares were sold on the market.
The RSU grant, originally awarded on June 2 2025, vests over four years: 3,212 shares vested on June 2 2026 and further tranches of 3,212, 3,211 and 3,211 shares are scheduled to vest annually through June 2 2029, subject to award conditions.
Neurocrine Biosciences Chief Scientific Officer Jude Onyia exercised stock options and sold shares on June 1, 2026. He exercised options for 11,000 shares of common stock at an exercise price of $84.74 per share and sold 11,000 shares in an open-market transaction at a weighted average price of $160.2464 per share, with sale prices ranging from $160.00 to $160.66. After these transactions, he directly holds 25,846 shares of common stock and 13,268 non-qualified stock options. The sale was executed by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 25, 2026, which the company’s policy does not allow him to amend after adoption.
NEUROCRINE BIOSCIENCES INC Chief Regulatory Officer Ingrid Delaet reported an option exercise combined with a routine share sale. On May 29, 2026, she exercised non-qualified stock options for 2,261 shares of common stock at an exercise price of $79.02 per share and sold 2,261 shares in an open-market transaction at $156.71 per share. After these transactions, she directly held 16,225 shares of common stock. The sale was executed by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026, which company policy does not allow her to amend or modify after adoption.
Notification of proposed sale of Common Stock under Rule 144. The filing lists 24,965 shares of Common Stock to be sold on 06/02/2026 described as resulting from an Exercise of Stock Options. The report also lists 9,879 Restricted and Performance Stock Units (02/08/2021) and 2,093 previously exercised stock options (08/04/2020).
The broker is listed as Morgan Stanley Smith Barney LLC and the execution venue is shown as NASDAQ.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting the proposed sale of 11,000 shares of Common Stock tied to an Exercise of Stock Options dated 06/01/2026. The filing shows associated dollar amounts of $1,741,300.00 and $1,710,865.20, and references 10b5-1 sales activity on 05/27/2026.
Neurocrine Biosciences Chief Scientific Officer Jude Onyia exercised options for 11,000 shares of common stock at $84.74 per share and, on the same day, sold 11,000 shares in open-market transactions at a weighted average price of $155.5332 per share.
The sale was carried out by a broker under a pre-arranged Rule 10b5-1 trading plan adopted on February 25, 2026. Following these transactions, Onyia directly holds 25,846 shares of common stock and 24,268 non-qualified stock options.
NEUROCRINE BIOSCIENCES INC director Kevin Charles Gorman received a new stock option grant. He was awarded options on 5,248 shares of common stock at an exercise price of $155.83 per share. The options vest in 12 monthly installments beginning June 27, 2026 and expire on May 27, 2036.
POPS RICHARD F reported acquisition or exercise transactions in this Form 4 filing.
NEUROCRINE BIOSCIENCES INC director Richard F. Pops received a grant of 2,567 Restricted Stock Units (RSUs). Each RSU represents one share of common stock upon vesting, and all 2,567 RSUs are scheduled to vest in full on May 27, 2027. Following this compensation award, Pops holds 2,567 RSUs directly.
NEUROCRINE BIOSCIENCES INC director Gary A. Lyons received new equity awards as part of his compensation. On May 27, 2026, he was granted non-qualified stock options for 2,624 shares of common stock at an exercise price of $155.83 per share, vesting in 12 monthly installments beginning June 27, 2026.
He also received 1,284 Restricted Stock Units, each representing one share of common stock upon vesting. These RSUs will vest in full on May 27, 2027. The filing shows these as direct holdings and reflects routine, compensation-related acquisitions rather than open-market buying or selling.
Mercier Johanna reported acquisition or exercise transactions in this Form 4 filing.
Neurocrine Biosciences director Johanna Mercier received a grant of 2,567 restricted stock units (RSUs). Each RSU represents the right to receive one share of Neurocrine Biosciences common stock upon vesting. The RSUs will vest in full on May 27, 2027, and her direct holdings after this grant total 2,567 RSUs.